Minimizing prostate brachytherapy-related morbidity

Urology

Volumn 62, Issue 5, 2003, Pages 786-792

  Merrick, Gregory S ^a   Wallner, Kent E ^b   Butler, Wayne M ^b  

^a WHEELING HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; IODINE 125; PALLADIUM 103; PREDNISONE; RECOMBINANT HORMONE; TAMSULOSIN;

BEAM THERAPY; BLADDER; BRACHYTHERAPY; CLINICAL TRIAL; DISEASE EXACERBATION; DYSURIA; EDEMA; ERECTILE DYSFUNCTION; HEMATURIA; HORMONAL THERAPY; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROCTITIS; PROPHYLAXIS; PROSTATE CANCER; PROSTATITIS; RADIATION DOSE; RECTUM DISEASE; RECTUM FISTULA; RECTUM ULCER; REVIEW; TRANSURETHRAL RESECTION; URETHRA STRICTURE; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION; URINE RETENTION;

EID: 0242495806     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00558-2     Document Type: Review

References (49)

1. Merrick G.S., Wallner K.E., Butler W.M. Permanent interstitial brachytherapy in the management of carcinoma of the prostate gland. J Urol. 169:2003;1643-1652.
2. Merrick G.S., Butler W.M., Dorsey A.T., et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol. 7:2001;233-240.
3. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol (in press).
4. Merrick G.S., Butler W.M., Galbreath R.W., et al. The relationship between percent positive biopsies and biochemical outcome following permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 52:2002;664-673.
5. Lee W.R., Hall M.C., McQuellon R.P., et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;614-623.
6. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 20:2002;557-566.
7. Talcott J.A., Clark J.A., Stark P.C., et al. Long-term treatment related complications of brachytherapy for early prostate cancer a survey of patients previously treated. J Urol. 166:2001;494-499.
8. Merrick GS, Butler WM, Wallner KE, et al. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56: 454-461, 2003.
9. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
10. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys. 52:2002;461-468.
11. 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 50:2001;335-341.
12. Merrick G.S., Butler W.M., Wallner K.E., et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys. 54:2002;1055-1062.
13. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys. 52:2002;453-460.
14. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;121-128.
15. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.
16. Landis P., Wallner K., Locke J., et al. Late urinary function after prostate brachytherapy. Brachytherapy. 1:2002;21-26.
17. Thomas M.D., Cormack R., Tempany C.M., et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;905-908.
18. Gray G., Wallner K., Roof J., et al. Cystourethroscopic findings before and after prostate brachytherapy. Tech Urol. 6:2000;109-111.
19. Merrick G.S., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha blockers following permanent prostate brachytherapy. Urology. 60:2002;650-655.
20. Desai J., Stock R.G., Stone N.N., et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
21. Wallner K., Merrick G., True L., et al. I-125 versus Pd-103 for low-risk prostate cancer morbidity outcomes from a prospective randomized multicenter trial. Cancer J Sci Am. 8:2002;67-73.
22. Merrick G.S., Butler W.M., Wallner K.E., et al. Dysuria following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 55:2003;979-985.
23. Narayan P., McKay J., Doyle C. A six-week double-blind pilot study of tamsulosin versus placebo in patients with chronic non-bacterial prostatitis/chronic pelvic pain. J Urol. 167:(suppl):2002;24.
24. Merrick G.S., Butler W.M., Galbreath R.W., et al. The relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology. 57:2001;524-529.
25. Stone N.N., Stock R.G. Complications following permanent prostate brachytherapy. Eur Urol. 41:2002;427-433.
26. Merrick GS, Butler WM, Wallner KE, et al. The effect of transurethral resection on urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (in press).
27. Merrick G.S., Butler W.M., Dorsey A.T., et al. Influence of prophylactic dexamethasone on edema following prostate brachytherapy. Tech Urol. 6:2000;117-122.
28. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
29. Leibovich B.C., Blute M.L., Bostwick D.G., et al. Proximity of prostate cancer to the urethra implications for minimally invasive ablative therapies. Urology. 56:2000;726-729.
30. Jones S., Wallner K., Merrick G., et al. Clinical correlates of high intraprostatic brachytherapy dose volumes. Int J Radiat Oncol Biol Phys. 53:2002;328-333.
31. Barker J., Wallner K., Merrick G. Hematuria after prostate brachytherapy. Urology. 61:2003;408-411.
32. Merrick G.S., Butler W.M., Dorsey A.T., et al. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 43:1999;1021-1027.
33. Merrick GS, Butler WM, Wallner KE, et al. Rectal function following brachytherapy: results of two prospective randomized trials. Brachytherapy (in press).
34. Merrick GS, Butler WM, Wallner KE, et al. Late rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 57: 42-48, 2003.
35. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 48:2000;119-124.
36. Waterman F.M., Dicker A.P. Effect of post-implant edema on rectal dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 45:1999;571-576.
37. Howard A., Wallner K., Han B., et al. Clinical course and dosimetry of rectal fistulas after prostate brachytherapy. J Brachyther Int. 17:2001;37-42.
38. Merrick G.S., Butler W.M., Dorsey A.T., et al. The effect of constipation on rectal dosimetry following prostate brachytherapy. Med Dosim. 25:2000;237-241.
39. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II) volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 49:2001;685-698.
40. Sanguineti G., Agostinelli S., Foppiano P., et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer. 86:2002;1843-1847.
41. Merrick GS, Butler WM, Wallner KE, et al. The influence of hormonal therapy on late rectal function following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (in press).
42. Merrick G.S., Butler W.M., Dorsey A.T., et al. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy induced erectile dysfunction. Int J Radiat Oncol Biol Phys. 46:2000;1069-1074.
43. Merrick G.S., Wallner K., Butler W.M., et al. Short-term sexual function after prostate brachytherapy. Int J Cancer (Radiat Oncol Invest). 96:2001;313-319.
44. Merrick G.S., Butler W.M., Galbreath R.W., et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 52:2002;893-902.
45. Stock R.G., Kao J., Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol. 165:2001;436-439.
46. Potters L., Torre T., Fearn P.A., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 50:2001;1235-1242.
47. Merrick G.S., Butler W.M., Lief J.H., et al. The efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology. 53:1999;1112-1116.
48. McCullough A.R. Prevention and management of erectile dysfunction following radical prostatectomy. Urol Clin North Am. 28:2001;613-627.
49. Montorsi F., Maga T., Strambi L.F., et al. Sildenafil taken at bedtime significantly increases nocturnal erections results of a placebo-controlled study. Urology. 56:2000;906-911.